Blog
About

2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Commentaire de la rédaction à propos de l’article « De la querelle du quinquina à la querelle de l’hydroxychloroquine ou comment notre système de protection du médicament est mis à l’épreuve: une analyse historique, scientifique et juridique » Translated title: Commentary from the editors concerning the article âFrom the cinchona dispute to the hydroxychloroquine dispute, or how our drug protection system is being tested: A historical, scientific and legal analysisâ

      Me´decine & Droit

      Published by Elsevier Masson SAS.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          REFERS TO: https://doi.org/10.1016/j.meddro.2020.05.003 Le 27 mai 2020, le décret d’autorisation de l’hydroxychoroquine pour traiter la coronavirus disease 2019 (covid-19) a été abrogé par le gouvernement et cette substance ne peut être dorénavant autorisée que dans le cadre d’essais cliniques.

          Related collections

          Author and article information

          Journal
          Me´decine & Droit
          Published by Elsevier Masson SAS.
          1246-7391
          1246-7391
          20 August 2020
          20 August 2020
          Article
          S1246-7391(20)30056-7
          10.1016/j.meddro.2020.06.001
          7438222
          © 2020 Published by Elsevier Masson SAS.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          Categories
          Article

          Comments

          Comment on this article